STAT

The FDA may move to shorten that grim list of side effects in every drug ad. Advertising execs can’t wait

The FDA may relax the rules that force drug makers to cram long lists of potential side effects into their ads. The ad companies can't wait to get creative.

Warning: Watching TV drug ads may put you to sleep.

That’s no surprise to many of us who’ve heard about the countless ways prescription drugs can harm us. But now, the Food and Drug Administration is considering whether bombarding consumers with every last potential side effect might be overkill. The agency, which approves prescription drugs and oversees how they’re marketed, is proposing a new study to look at whether patients are being “over-warned” to the point that they stop paying attention.

“You don’t even bat an eyelash that this product could kill you, which is kind of an indicator of how ubiquitous it is,” said Holly Fernandez Lynch, a bioethicist at Harvard Law School. Experts said the research might be a sign the FDA could loosen up regulations that require drug companies

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.

Related Books & Audiobooks